CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: In patients having achieved complete cytogenetic remission following IM therapy, referred to as CML-IM patients, we observed a recovery of innate CD8(+) T cells (Figure 3A, left panel) in CML-IM patients (5.4% ± 0.5; n = 6 vs. 2.3% ± 0.6; n = 7 in CML-CP patients), back close to the proportions found in HD (7.8% ± 0.9; n = 16), while Eomes expression (Figure 3A, right panel) was increased in CML-IM patients (MFI: 2.5 ± 0.5; n = 6) as compared with CML-CP patients (1.4 ± 0.2; n = 7) and was partially restored relative to HD (MFI: 4.0 ± 0.5; n = 16).